Fairvalue-Calculator Fairvalue-Calculator
EN DE

Pilulka Lékárny a.s. (PINK) Fair Value & Analysis

Healthcare · CZ · Market cap 333M CZK

Price121.00 CZK
Fair Value105.11 CZK
Upside-13.1%
Quality92/100
Evidence: Low Range 75.17 CZK – 135.05 CZK

Fair value as of: Jun 24, 2026

Analysis

Pilulka Lékárny a.s. (PINK) currently trades at 121.00 CZK, while our model-based Fair Value estimate is 105.11 CZK — implying the stock looks roughly 13.1% overvalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Pilulka Lékárny a.s. operates a network of pharmacy stores under the Pilulka brand in the Czech Republic, Slovakia, Romania, Hungary, and Austria. The company distributes medicinal products; online sale of pharmacy and related goods for health; and healthy lifestyle and services under the Pilulka brand. It also operates Internet portals, such as Pilulka.cz, Pilulka.sk, Pilulka.ro, Pilulka.hu, and Pilulka.at, as well as an e-shop. Pilulka Lékárny a.s. was founded in 2013 and is headquartered in Prague, the Czech Republic.

Open the full interactive analysis →

Similar stocks

JD Health International Inc (JDHIF) +404% Alibaba Health Information Technology Limited (ALBBY) -19% Raia Drogasil S.A (RADL3) -8% Yifeng Pharmacy Chain Co (603939) +5% Clicks Group (CLCGY) +23% Sugi Holdings (SGIPF) +295%

Frequently asked questions

Is Pilulka Lékárny a.s. (PINK) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 105.11 CZK versus a price of 121.00 CZK — about −13% (overvalued). Model-based estimate, not financial advice.
What is the fair value of PINK?
Our 21-model fair value for Pilulka Lékárny a.s. is 105.11 CZK (as of Jun 24, 2026), built from audited fundamentals. The current price is 121.00 CZK.
What is the quality score of PINK?
Pilulka Lékárny a.s. has a Quality Score of 92/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.